Adlai Nortye

Adlai Nortye

Adlai Nortye was incorporated in the Cayman Islands and operates through subsidiaries in China and the United States, advancing a pipeline of immuno-oncology drug candidates. The company's lead asset, buparlisib (AN2025), is a pan-PI3K inhibitor that entered Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinoma, with development supported by a licensing agreement with Novartis signed in 2017. A second clinical-stage candidate, AN0025, is an EP4 antagonist being evaluated in combination with standard-of-care therapies for solid tumors. The firm's operations reflect a trans-Pacific structure common among pre-revenue biotechs seeking both Chinese regulatory pathways and eventual access to US and European capital markets. The company filed for an initial public offering on the Nasdaq in 2021, seeking to raise approximately $100 million, but the offering did not price. In September 2023, Adlai Nortye completed a downsized IPO on the Nasdaq, raising $57.5 million by offering 2.5 million American depositary shares at a reduced price of $23.00 per share (per SEC filings, 2023). Prior to the public listing, the firm raised private capital from a syndicate including OrbiMed, Hermed Capital, and Matrix Partners China. As of its most recent quarterly filing, the firm employed fewer than 100 staff across its Hangzhou, Beijing, and New Jersey offices. Clinical operations are concentrated in China, where patient recruitment is faster for the cancer indications the company targets, while early discovery and business development functions are split between the US and China. The firm has no disclosed family-office backing or single-family governance structure, distinguishing it from wealth-management firms that appear in Altss profiles. The structural differentiator for Adlai Nortye lies in its licensing-and-development model rather than in-house discovery. Both AN2025 and AN0025 were in-licensed from global pharmaceutical companies (Novartis and Eisai, respectively), which meant the firm was born from dealmaking rather than academic research. This model reduces early-stage scientific risk but places extraordinary pressure on clinical execution and the capacity to raise follow-on capital in the public markets — a governance challenge monitored closely by institutional biotech investors.